Umair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, Xiang Zhou, Seungbin Han, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Thorsten Keller, Ann-Katrin Regensburger, Eva Teufel, Julia Mersi, Max Bittrich, Franziska Seifert, Malik S Haider, Leo Rasche, Jost Hillenkamp, Hermann Einsele, Daniel Kampik, K Martin Kortüm, Johannes M Waldschmidt
Belantamab mafodotin (belantamab) is a first-in-class anti-BCMA antibody-drug conjugate approved for the treatment of triple-class refractory multiple myeloma. It provides a unique therapeutic option for patients ineligible for CAR-T and bispecific antibody therapy, and/or patients progressing on anti-CD38 treatment where CAR-T and bispecifics might be kept in reserve. Wider use of the drug can be challenged by its distinct ocular side effect profile, including corneal microcysts and keratopathy. While dose reduction has been the most effective way to reduce these toxicities, the underlying mechanism of this BCMA off-target effect remains to be characterized...
April 4, 2024: Haematologica